Investigation Report on China Alteplase Market, 2010-2019
Description
As the second generation of thrombolytic, anticoagulant factor alteplase can dissolve blood clots by activating plasminogen and then dissolving fibrin. For acute myocardial infarction, alteplase given intravenously can unclog coronary artery.
Plasmin working by resolving fibrous protein in clots takes up a small market share while plasminogen activator represented by alteplase developed by Genentech is the mainstream product in global market. In China, only Actilyse, a life-saving injection of Boehringer-Ingelheim AG with approved indications of acute myocardial infarction, (acute) pulmonary embolism and acute ischemic stroke is available. Having been approved by over 85 countries in the world, actilyse is marketed by Boehringer-Ingelheim AG in areas outside North America and Japan, by Genentech under the trade name of Activase since 1996 in the US and by Roche since 1999 in the Canada. Ever since its appearance, actilyse has been widely used to treat acute ischemic stroke.
According to CRI’s market survey, the annual sales value of alteplase in sample hospitals rose from less than CNY 12 million in 2005 to over CNY 40 million in 2014 and CAGR during this period reached 16.3%. Boehringer-Ingelheim AG (Germany) and Shandong Ahua Biopharmaceutical Co., Ltd dominate the market with the former having the largest market share of over 90% for sales value in 2014.
Currently, the number of cardiovascular disease reports an increasing number of younger patients, high fatality and disability in China. According to the Report on Cardiovascular Diseases in China (2013), there are about 290 million people suffering from cardiovascular diseases. Since 2005, acute myocardial infarction has reported an increasing fatality and each year only 5% of 2.5 million patients per year can get treatment. Hence the vast market for anti-clotting drugs in China.
Readers can get at least the following information through this report:
As the second generation of thrombolytic, anticoagulant factor alteplase can dissolve blood clots by activating plasminogen and then dissolving fibrin. For acute myocardial infarction, alteplase given intravenously can unclog coronary artery.
Plasmin working by resolving fibrous protein in clots takes up a small market share while plasminogen activator represented by alteplase developed by Genentech is the mainstream product in global market. In China, only Actilyse, a life-saving injection of Boehringer-Ingelheim AG with approved indications of acute myocardial infarction, (acute) pulmonary embolism and acute ischemic stroke is available. Having been approved by over 85 countries in the world, actilyse is marketed by Boehringer-Ingelheim AG in areas outside North America and Japan, by Genentech under the trade name of Activase since 1996 in the US and by Roche since 1999 in the Canada. Ever since its appearance, actilyse has been widely used to treat acute ischemic stroke.
According to CRI’s market survey, the annual sales value of alteplase in sample hospitals rose from less than CNY 12 million in 2005 to over CNY 40 million in 2014 and CAGR during this period reached 16.3%. Boehringer-Ingelheim AG (Germany) and Shandong Ahua Biopharmaceutical Co., Ltd dominate the market with the former having the largest market share of over 90% for sales value in 2014.
Currently, the number of cardiovascular disease reports an increasing number of younger patients, high fatality and disability in China. According to the Report on Cardiovascular Diseases in China (2013), there are about 290 million people suffering from cardiovascular diseases. Since 2005, acute myocardial infarction has reported an increasing fatality and each year only 5% of 2.5 million patients per year can get treatment. Hence the vast market for anti-clotting drugs in China.
Readers can get at least the following information through this report:
- market size of alteplase in China
- competitive landscape of alteplase market in China
- price of alteplase made by different enterprises in China
- market outlook of alteplase in China
- manufacturers of anti-clotting drugs
- investors/research institutions interested in Chinese medicine market
- -any interest in Chinese medicine market, please contact CRI for customized survey service
1 RELATED CONCEPTS OF ALTEPLASE
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF ALTEPLASE IN CHINA
2.1 Patent and Approval Information of Alteplase in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON ALTEPLASE SALES IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR ALTEPLASE MANUFACTURERS IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF ALTEPLASE IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF ALTEPLASE IN CHINESE HOSPITALS IN 2014
6.1 Boehringer-Ingelheim AG (Germany)
6.2 Shandong Ahua Biopharmaceutical Co., Ltd
7 MAJOR MANUFACTURERS OF ALTEPLASE IN CHINESE MARKET, 2010-2014
7.1 Boehringer-Ingelheim AG (Germany)
7.2 Shandong Ahua Biopharmaceutical Co., Ltd
8 MARKET OUTLOOK OF ALTEPLASE IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
TABLE OF SELECTED CHARTS
Chart Approval Information of Alteplase in China
Chart Alteplase Sales in China
Chart Sales Value of Alteplase in China, 2010-2014
Chart Sales Value of Alteplase in Some Regions in China, 2010-2014
Chart Sales Volume of Alteplase in China, 2010-2014
Chart Sales Volume of Alteplase in Some Regions in China, 2010-2014
Chart Sales Value and Market Share of Alteplase Made by Boehringer-Ingelheim (Germany) in China, 2010-2014
Chart Sales Value and Market Share of Alteplase Made by Shandong Ahua in China, 2010-2014
Chart Sales Value and Market Share of Alteplase Injection in China, 2010-2014
Chart Sales Volume and Market Share of Alteplase Tablet in China, 2010-2014
Chart Price of Alteplase Made by Boehringer-Ingelheim (Germany) in Some Chinese Cities in 2014
Chart Price of Alteplase Made by Shandong Ahua Biopharmaceutical Co., Ltd in Some Chinese Cities in 2014
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF ALTEPLASE IN CHINA
2.1 Patent and Approval Information of Alteplase in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON ALTEPLASE SALES IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR ALTEPLASE MANUFACTURERS IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF ALTEPLASE IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF ALTEPLASE IN CHINESE HOSPITALS IN 2014
6.1 Boehringer-Ingelheim AG (Germany)
6.2 Shandong Ahua Biopharmaceutical Co., Ltd
7 MAJOR MANUFACTURERS OF ALTEPLASE IN CHINESE MARKET, 2010-2014
7.1 Boehringer-Ingelheim AG (Germany)
7.2 Shandong Ahua Biopharmaceutical Co., Ltd
8 MARKET OUTLOOK OF ALTEPLASE IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
TABLE OF SELECTED CHARTS
Chart Approval Information of Alteplase in China
Chart Alteplase Sales in China
Chart Sales Value of Alteplase in China, 2010-2014
Chart Sales Value of Alteplase in Some Regions in China, 2010-2014
Chart Sales Volume of Alteplase in China, 2010-2014
Chart Sales Volume of Alteplase in Some Regions in China, 2010-2014
Chart Sales Value and Market Share of Alteplase Made by Boehringer-Ingelheim (Germany) in China, 2010-2014
Chart Sales Value and Market Share of Alteplase Made by Shandong Ahua in China, 2010-2014
Chart Sales Value and Market Share of Alteplase Injection in China, 2010-2014
Chart Sales Volume and Market Share of Alteplase Tablet in China, 2010-2014
Chart Price of Alteplase Made by Boehringer-Ingelheim (Germany) in Some Chinese Cities in 2014
Chart Price of Alteplase Made by Shandong Ahua Biopharmaceutical Co., Ltd in Some Chinese Cities in 2014
